Adjusted EBITDA margin to be around 20.8% in Q4 (vs 19.5% in Q3) Organic growth is healthy at +4.6% QoQ USD, 5.7% QoQ CC and contribution days in Q3. Order intake is healthy at $247 mn (29% YoY, vs FY21 average of ~$195 mn) including one large 6-year deal of $45 mn from European Public sector client. Next 12 months' executable order book is $701 Mn, +2% QoQ,...